JPWO2020072536A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020072536A5 JPWO2020072536A5 JP2021542089A JP2021542089A JPWO2020072536A5 JP WO2020072536 A5 JPWO2020072536 A5 JP WO2020072536A5 JP 2021542089 A JP2021542089 A JP 2021542089A JP 2021542089 A JP2021542089 A JP 2021542089A JP WO2020072536 A5 JPWO2020072536 A5 JP WO2020072536A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cells
- seq
- γδt
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025085673A JP2025134707A (ja) | 2018-10-01 | 2025-05-22 | 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862739822P | 2018-10-01 | 2018-10-01 | |
| US62/739,822 | 2018-10-01 | ||
| PCT/US2019/054132 WO2020072536A1 (en) | 2018-10-01 | 2019-10-01 | COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON- ENGINEERED γδ-Τ CELLS FOR TREATMENT OF HEMATOLOGICAL TUMORS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025085673A Division JP2025134707A (ja) | 2018-10-01 | 2025-05-22 | 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022501074A JP2022501074A (ja) | 2022-01-06 |
| JP2022501074A5 JP2022501074A5 (https=) | 2022-10-12 |
| JPWO2020072536A5 true JPWO2020072536A5 (https=) | 2022-10-12 |
| JP7687952B2 JP7687952B2 (ja) | 2025-06-03 |
Family
ID=68393055
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021542089A Active JP7687952B2 (ja) | 2018-10-01 | 2019-10-01 | 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 |
| JP2025085673A Pending JP2025134707A (ja) | 2018-10-01 | 2025-05-22 | 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025085673A Pending JP2025134707A (ja) | 2018-10-01 | 2025-05-22 | 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210388100A1 (https=) |
| EP (1) | EP3860645A1 (https=) |
| JP (2) | JP7687952B2 (https=) |
| KR (1) | KR20210070330A (https=) |
| CN (1) | CN113056283A (https=) |
| AU (1) | AU2019354391A1 (https=) |
| BR (1) | BR112021006182A2 (https=) |
| CA (1) | CA3115139A1 (https=) |
| EA (1) | EA202190926A1 (https=) |
| IL (1) | IL281922A (https=) |
| MX (1) | MX2021003745A (https=) |
| SG (1) | SG11202103235PA (https=) |
| WO (1) | WO2020072536A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108395482B (zh) | 2017-02-08 | 2021-02-05 | 西比曼生物科技（香港）有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| MX2022000896A (es) * | 2019-07-24 | 2022-02-14 | Regeneron Pharma | Receptores de antigenos quimericos con especificidad por mage-a4 y usos de los mismos. |
| CN113402612A (zh) | 2020-03-17 | 2021-09-17 | 西比曼生物科技（香港）有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
| CN113667640B (zh) * | 2021-08-27 | 2022-09-02 | 广州百暨基因科技有限公司 | CAR-γδT细胞的制备方法 |
| IL313297A (en) * | 2021-12-05 | 2024-08-01 | Adicet Therapeutics Inc | Treatment of b cell malignancies |
| CN116574194A (zh) * | 2022-06-02 | 2023-08-11 | 深圳普瑞金生物药业股份有限公司 | 嵌合抗原受体及其用途 |
| CA3278900A1 (en) | 2023-03-31 | 2024-10-03 | AbelZeta Inc. | BISPECIFIC CHIMERIC ANTIGENIC RECEPTORS TARGETING CD20 AND BCMA |
| CN121419987A (zh) * | 2023-07-07 | 2026-01-27 | 南京传奇生物科技有限公司 | 蛋白质及其用途 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101928344B (zh) * | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
| JP5139800B2 (ja) * | 2004-06-03 | 2013-02-06 | ノビミューン エスアー | 抗ｃｄ３抗体およびその使用方法 |
| AU2005336093B2 (en) | 2004-10-08 | 2011-02-24 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Adoptive immunotherapy with enhanced T lymphocyte survival |
| KR20080031001A (ko) * | 2005-06-02 | 2008-04-07 | 아스트라제네카 아베 | Ｃｄ20에 대한 항체 및 그의 용도 |
| NZ583019A (en) * | 2007-07-31 | 2011-05-27 | Regeneron Pharma | Human antibodies to human cd20 and method of using thereof |
| WO2010042490A1 (en) | 2008-10-06 | 2010-04-15 | Boston Medical Center Corporation | A single lentiviral vector system for induced pluripotent (ips) stem cells derivation |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CN103635573B (zh) | 2011-05-19 | 2016-05-11 | 分子医学研究所 | 包含γδT细胞的淋巴细胞系、其组合物及生产方法 |
| CN104768581A (zh) * | 2012-09-07 | 2015-07-08 | 吉宁特有限公司 | II型抗CD20抗体与选择性Bcl-2抑制剂的组合治疗 |
| CN104087607B (zh) | 2013-04-01 | 2017-06-20 | 科济生物医药（上海）有限公司 | 编码嵌合抗原受体蛋白的核酸及表达嵌合抗原受体蛋白的t淋巴细胞 |
| JP2016539929A (ja) | 2013-10-25 | 2016-12-22 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 免疫療法のためのポリクローナルγδＴ細胞 |
| CN107075480A (zh) | 2014-07-09 | 2017-08-18 | Tc生物制药有限公司 | γδT细胞及其用途 |
| GB201506423D0 (en) * | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| TWI750110B (zh) * | 2014-07-21 | 2021-12-21 | 瑞士商諾華公司 | 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症 |
| ES2777305T5 (en) * | 2014-09-04 | 2025-09-30 | Cellectis | Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy |
| WO2016081518A2 (en) * | 2014-11-17 | 2016-05-26 | Adicet Bio, Inc. | Engineered gamma delta t-cells |
| GB201507368D0 (en) * | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| AU2016274633B2 (en) | 2015-06-09 | 2022-04-21 | Gammadelta Therapeutics Ltd | Methods for the production of TCR gamma delta+ T cells |
| US10639329B2 (en) * | 2015-06-12 | 2020-05-05 | Lentigen Technology, Inc. | Method to treat cancer with engineered T-cells |
| WO2017083750A1 (en) | 2015-11-11 | 2017-05-18 | Intrexon Corporation | Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies |
| EP3454870A4 (en) | 2016-05-12 | 2020-03-04 | Adicet Bio Inc. | METHOD FOR SELECTIVE EXPANSION OF GAMMA DELTA T CELL POPULATIONS AND COMPOSITIONS THEREOF |
| KR20240005168A (ko) | 2016-11-04 | 2024-01-11 | 2세븐티 바이오, 인코포레이티드 | 항-bcma car t 세포 조성물 |
| JP2019535262A (ja) | 2016-11-11 | 2019-12-12 | オートラス リミテッド | キメラ抗原受容体 |
| US11851491B2 (en) | 2016-11-22 | 2023-12-26 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| ES3035979T3 (en) | 2017-01-23 | 2025-09-11 | Crage Medical Co Ltd | Bcma-targeting antibody and use thereof |
| EP3580331B1 (en) * | 2017-02-08 | 2022-06-01 | Agency For Science, Technology And Research | Gamma delta t cells and a method of augmenting the tumoricidal activity of the same |
| GB2562774A (en) | 2017-05-25 | 2018-11-28 | Mcdonald Michael | Genetic construct |
| EP3561053A1 (en) * | 2018-04-26 | 2019-10-30 | Baylor College of Medicine | Immune effector cells and molecular adaptors with an antigen cytokine complex for effective cancer immunotherapy |
| EP3784256A4 (en) * | 2018-04-27 | 2022-06-29 | Baylor College of Medicine | Car t cells with one or more interleukins |
| CN108588023B (zh) * | 2018-05-09 | 2020-02-14 | 河北森朗生物科技有限公司 | 一种生产嵌合抗原受体修饰的γδT细胞的方法 |
| CA3112584A1 (en) * | 2018-09-17 | 2020-03-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bicistronic chimeric antigen receptors targeting cd19 and cd20 and their uses |
-
2019
- 2019-10-01 AU AU2019354391A patent/AU2019354391A1/en active Pending
- 2019-10-01 EA EA202190926A patent/EA202190926A1/ru unknown
- 2019-10-01 EP EP19795699.8A patent/EP3860645A1/en active Pending
- 2019-10-01 MX MX2021003745A patent/MX2021003745A/es unknown
- 2019-10-01 BR BR112021006182-7A patent/BR112021006182A2/pt unknown
- 2019-10-01 CA CA3115139A patent/CA3115139A1/en active Pending
- 2019-10-01 WO PCT/US2019/054132 patent/WO2020072536A1/en not_active Ceased
- 2019-10-01 SG SG11202103235PA patent/SG11202103235PA/en unknown
- 2019-10-01 CN CN201980070384.5A patent/CN113056283A/zh active Pending
- 2019-10-01 KR KR1020217012805A patent/KR20210070330A/ko active Pending
- 2019-10-01 US US17/281,574 patent/US20210388100A1/en active Pending
- 2019-10-01 JP JP2021542089A patent/JP7687952B2/ja active Active
-
2021
- 2021-03-31 IL IL281922A patent/IL281922A/en unknown
-
2025
- 2025-05-22 JP JP2025085673A patent/JP2025134707A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7766662B2 (ja) | 活性化可能なサイトカインポリペプチド及びその使用方法 | |
| CN111655716B (zh) | 基于il-15的与il-7和il-21的融合体 | |
| TWI853818B (zh) | 細胞激素融合蛋白及其用途 | |
| KR102874838B1 (ko) | 마스킹된 사이토카인 폴리펩타이드 | |
| JP7282383B2 (ja) | タンパク質性ヘテロ二量体及びその用途 | |
| CA3055318C (en) | IL-15-BASED FUSION PROTEINS SPECIFIC TO IL-12 AND IL-18 | |
| ES2752248T3 (es) | Heterodímero proteínico y uso del mismo | |
| JP6395834B2 (ja) | ＣＤ３２ＢおよびＣＤ７９ｂに結合可能な二重特異性の一価のＦｃダイアボディ、ならびにその使用 | |
| AU2014337367B2 (en) | Peptidic chimeric antigen receptor T cell switches and uses thereof | |
| JP6911105B2 (ja) | 抗体重鎖不変部位ヘテロ二量体（ｈｅｔｅｒｏｄｉｍｅｒｉｃ Ｆｃ）に融合したＩＬ−２１（ｈｅｔｅｒｏｄｉｍｅｒｉｃ Ｆｃ−ｆｕｓｅｄ ＩＬ−２１）及びこれを含む薬剤学的組成物 | |
| JP2022137288A (ja) | ヘテロダイマーＦｃ融合サイトカインおよびそれを含む医薬組成物 | |
| KR20170094341A (ko) | 인터류킨 15 단백질 복합체 및 그의 용도 | |
| WO2019129053A1 (zh) | 以抗体Fc区为骨架的融合蛋白二聚体及其应用 | |
| JP2022538139A (ja) | 変異体インターロイキン－２及び抗ｃｄ８抗体を含む免疫複合体 | |
| JP2006517191A (ja) | 共刺激因子を用いた併用療法 | |
| JP2005520853A (ja) | 蛋白質ワクチン接種の有効なアジュバントとしての抗体融合蛋白質 | |
| JP2019528683A (ja) | 多量体ｇｉｔｒ結合分子及びその使用 | |
| KR20200123782A (ko) | 암치료를 위해 화학치료제와 병용된 다중결합 항-dr5 결합분자의 용도 | |
| US10329350B2 (en) | Method for producing a multivalent fab fragment with collagen-like peptide | |
| CA3058427C (en) | Alt-803 in combination with anti-cd38 antibody for cancer therapies | |
| JP2022532249A (ja) | インターロイキンタンパク質の類似体と組み合わせて癌を処置するための治療用組成物及び方法 | |
| WO2018199595A1 (ko) | 4-1bbl 변이체 및 이를 포함하는 융합 단백질 | |
| CN103897057B (zh) | 多价抗体片段与其三聚复合物 | |
| JPWO2020072536A5 (https=) | ||
| EP4314073A1 (en) | Upar antibodies and fusion proteins with the same |